ClinicalTrials.gg
RecruitingNCT07491302Thumbs-upUpdated Oct 5, 2026

Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection

A Phase 2 interventional study of Platelet-Rich Plasma (PRP) Injections and Saline (0.9% NaCl) in Thumb Osteoarthritis, sponsored by Goed Medisch Centrum. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Goed Medisch Centrum · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 5, 2026Now RecruitingFirst site in Netherlands+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing platelet rich plasma in Osteoarthritis — 6 open to participants now, 6 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis.

Planned enrollment
12th of 28
88 · median 70
Started
2026
the only one that year
Phase 2
2 of 28
2 open now
Registered
26th of 28
by date
Lead sponsor
1 of 28
Goed Medisch Centrum

Among the 28 studies testing platelet rich plasma in Osteoarthritis, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 2, and was the 26th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

6 of the 28 studies testing platelet rich plasma in Osteoarthritis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing platelet rich plasma in Osteoarthritis, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether platelet-rich plasma (PRP) injections improve pain and function in adults with thumb base osteoarthritis (CMC-I OA).

The main questions it aims to answer are:

Does a PRP injection reduce pain compared to a placebo (saline) injection? Does PRP improve hand function, strength, and thumb mobility? What adverse events occur following PRP treatment?

Researchers will compare PRP injections to a placebo injection (saline solution) to determine whether PRP is an effective treatment for CMC-I osteoarthritis.

Participants will:

Receive a single ultrasound-guided injection of PRP or placebo (saline) in the CMC-I joint.

Attend follow-up visits at 3, 6, 9, and 12 months for clinical assessments. Complete questionnaires on pain (VAS) and hand function (MHQ-DLV) at multiple time points.

Undergo physical examinations (grip strength, pinch strength, thumb motion). Undergo ultrasound evaluations to assess joint characteristics.

03

Conditions studied

  • Thumb Osteoarthritis

Browse trials for

Keywords

  • platelet-rich plasma
  • CMC-I joint
  • carpometacarpal joint osteoarthritis
  • Thumb base osteoarthritis
  • PRP injection
  • Placebo-controlled trial
  • Orthobiologics
  • Regenerative medicine
  • Ultrasound-guided injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Patients with an Eaton-littler score of I, II or III
  • Patients with uni- or bilateral CMC-I osteoarthritis
  • Non-responders to conservative therapy i.e., hand therapy and immobilisation after 3 months

Exclusion criteria

Exclusion Criteria:

  • Aged below 18
  • Patients with an Eaton-littler score of IV (STT arthrosis)
  • Surgical interventions of the CMC-I joint
  • A known articular systemic disease (e.g. rheumatoid arthritis) or additional hand osteoarthritis/ tenosynovitis or metabolic disease like diabetes mellitus
  • Patients with an infectious arthritis of CMC-I joint
  • A known psychiatric condition
  • Neuropathic chronic pain syndrome
  • Intra articular injection 6 months prior to inclusion
  • Smoking
  • Active use of statins
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Platelet-rich plasma group A

    Biological: Platelet-Rich Plasma (PRP) Injections

  • Placebo comparator
    Placebo group B

    Saline

    Drug: Saline (0.9% NaCl)

Interventions

  • BiologicalPlatelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Autologous platelet-rich plasma (PRP) is prepared from 90 mL of the participant's venous blood using a standardized two-step centrifugation protocol (ACP® Max system, Arthrex Inc.). The first centrifugation is performed at 3200 rpm for 9 minutes, followed by a second centrifugation at 1500 rpm for 5 minutes, resulting in approximately 2 mL of PRP. A single injection of 2 mL PRP is administered under sterile conditions and ultrasound guidance into the CMC-I joint, consisting of 1 mL intra-articular and 1 mL peri-articular injection. No repeated injections are performed.

  • DrugSaline (0.9% NaCl)

    Participants receive a placebo injection consisting of 2 mL sterile saline (0.9% NaCl), administered under sterile conditions and ultrasound guidance into the CMC-I joint. The injection protocol is identical to the PRP group, with 1 mL injected intra-articularly and 1 mL peri-articularly. To maintain blinding, participants in the placebo group undergo a venous blood draw mimicking the PRP preparation procedure; however, the collected blood is discarded. The duration and procedural steps are standardized to ensure comparable treatment conditions between groups. No repeated injections are performed.

    Also known as: Placebo injection

06

What researchers measure

Primary outcomes

  1. Clinical pain improvement: Visual Analog Scale (VAS) for pain

    Pain will be assessed using the Visual Analog Scale (VAS), a continuous scale ranging from 0 to 100, where 0 indicates no pain and 100 indicates worst imaginable pain. A decrease in VAS score reflects an improvement in pain.

    Time frame: 3, 6, 9 and 12 months

Secondary outcomes

  1. Functional improvement: Michigan Hand Outcomes Questionnaire (MHQ-DLV)

    Hand function will be assessed using the Michigan Hand Outcomes Questionnaire (MHQ), Dutch Language Version (MHQ-DLV). The MHQ is a patient-reported outcome measure consisting of multiple domains (including overall hand function, activities of daily living, pain, work performance, aesthetics, and patient satisfaction), each scored on a scale from 0 to 100. For all domains except pain, higher scores indicate better hand function and greater satisfaction. For the pain domain, higher scores indicate more severe pain.

    Time frame: 3, 6, 9 and 12 months

  2. Functional improvement: Grip and pinch test

    Time frame: 3, 6, 9 and 12 months

  3. Functional improvement: Opposition of the thumb (pollexograph)

    Time frame: 3, 6, 9 and 12 months

  4. Functional improvement: Kapandji Opposition Score

    Thumb opposition will be assessed using the Kapandji Opposition Score, a clinical scale ranging from 0 to 10, where 0 indicates no opposition and 10 indicates maximal opposition of the thumb across the palm. Higher scores indicate better thumb function and greater range of opposition.

    Time frame: 3, 6, 9 and 12 months

07

Study locations

1 of 1 sites recruiting
  • GOED Medisch Centrum
    Breda, North Brabant 4811HR, Netherlands
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 82 phase 2 interventional studies under Osteoarthritis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Apr 2026 → May 2026 and primary completion Mar 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartActual
May 20, 2026was Apr 2026
Primary completionEst.
May 2027was Mar 2027
CompletionEst.
Jun 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
1 site added — first site in Netherlands
Show site
  • GOED Medisch Centrum · Breda, Netherlands
Oct 5, 2026
Start date
Apr 2026→May 20, 2026 (actual)
Oct 5, 2026
Primary completion
Mar 2027→May 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Netherlands
    Show site
    • GOED Medisch Centrum · Breda, Netherlands
    Start date Apr 2026→May 20, 2026 (now actual)
    Primary completion Mar 2027→May 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07491302
Lead sponsor
Goed Medisch Centrum
Collaborators
Arthrex, Inc.
Responsible party
Evi Loos (Prinicpal Investigator, Goed Medisch Centrum) — Principal investigator
First posted
Mar 24, 2026
Start date
May 20, 2026
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion